drugset / Trial / NCT00354367

Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas

NCT00354367

Phase 3 Withdrawn UCB Pharma
RandomizedParallel-groupOpen-labelTreatment

Summary

To investigate the clinical efficacy of certolizumab pegol for fistula closure in Crohn's disease subjects with active draining fistulas.

Timeline

Start
2007-01
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Certolizumab Pegol Protein / enzyme biologic

Indications